Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA)

Acta Tropica

Volumn 128, Issue 3, 2013, Pages 528-535

  Firouzmand, Hengameh ^a,b   Badiee, Ali ^b   Khamesipour, Ali ^c   Heravi Shargh, Vahid ^b   Alavizadeh, Seyedeh Hoda ^b   Abbasi, Azam ^b   Jaafari, Mahmoud Reza ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant; DOTAP; Leishmaniasis; Nanoliposomes; SLA; Vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTIPROTOZOAL AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; NANOCARRIER; SOLUBLE LEISHMANIA ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY; ANTIGEN; CATION; CONCENTRATION (COMPOSITION); IMMUNE RESPONSE; LEISHMANIASIS; LIPID; PARASITE; RODENT; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; FEMALE; IMMUNOPROPHYLAXIS; IN VITRO STUDY; INFECTION PREVENTION; INFECTION SENSITIVITY; LEISHMANIASIS; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PATHOGEN LOAD; SPLEEN CELL; ZETA POTENTIAL;

LEISHMANIA MAJOR; MUS;

ADJUVANT; DOTAP; LEISHMANIASIS; NANOLIPOSOMES; SLA; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOOT; INJECTIONS, SUBCUTANEOUS; LEISHMANIA MAJOR; LEISHMANIASIS; LEISHMANIASIS VACCINES; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARASITE LOAD; QUATERNARY AMMONIUM COMPOUNDS; VACCINATION;

EID: 84892517256     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.07.021     Document Type: Article

References (61)

1. Almeida M.C., Vilhena V., Barral A., Barral-Netto M. Leishmanial infection: analysis of its first steps. A review. Memórias do Instituto Oswaldo Cruz 2003, 98:861-870.
2. Alvar J., Croft S.L., Kaye P., Khamesipour A., Sundar S., Reed S.G. Case study for a vaccine against leishmaniasis. Vaccine 2013, 31:229-244.
3. Badiee A., Heravi Shargh V., Khamesipour A., Jaafari M.R. Micro nanoparticle adjuvant for anti leishmanial vaccines: present and future trends. Vaccine 2013, 31:735-749.
4. Badiee A., Jaafari M.R., Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Experimental Parasitology 2007, 115:127-134.
5. Bainor A., Chang L., McQuade T.J., Webb B., Gestwicki J.E. Bicinchoninic acid (BCA) assay in low volume. Analytical Biochemistry 2010, 410:310-402.
6. Bhowmick S., Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert Opinion on Drug Delivery 2008, 5:789-803.
7. Bhowmick S., Ravindran R., Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 2007, 25:6544-6556.
8. Brewer J.M., Tetley L., Richmond J., Liew F.Y., Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. Journal of Immunology 1998, 161:4000-4007.
9. Brgles M., Habjanec L., Halassy B., Tomasic J. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine 2009, 27:5435-5442.
10. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., Alvar J., Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nature Reviews Microbiology 2007, 5:873-882.
11. Chen W., Yan W., Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunology, Immunotherapy 2008, 57:517-530.
12. Christensen D., Korsholm K.S., Andersen P., Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Review of Vaccines 2011, 10:513-521.
13. Christensen D., Korsholm K.S., Rosenkrands I., Lindenstrom T., Andersen P., Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Review of Vaccines 2007, 6:785-796.
14. Copland M.J., Rades T., Davies N.M., Baird M.A. Lipid based particulate formulations for the delivery of antigen. Immunology and Cell Biology 2005, 83:97-105.
15. D'Andrea A., Ma X., Aste-Amezaga M., Paganin C., Trinchieri G. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. Journal of Experimental Medicine 1995, 181:537-546.
16. Danesh-Bahreini M.A., Shokri J., Samiei A., Kamali-Sarvestani E., Barzegar-Jalali M., Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. International Journal of Nanomedicine 2011, 6:835-842.
17. Espuelas S. Delivery systems for the treatment and prevention of leishmaniasis. Gazeta Medica da Bahia 2009, 79:134-146.
18. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., Silverman C., Alving C.R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:358-362.
19. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunology Today 1990, 11:89-97.
20. Gregoriadis G., McCormack B., Obrenovic M., Perrie Y., Saffie R. Vaccine adjuvants. Preparation methods and research protocols. Liposomes as Immunological Adjuvants and Vaccine Carriers 2000, 137-150. Springer, New York. D.T. O'Hagan (Ed.).
21. Hafez I.M., Maurer N., Cullis P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Therapy 2001, 8:1188-1196.
22. Henriksen-Lacey M., Korsholm K.S., Andersen P., Perrie Y., Christensen D. Liposomal vaccine delivery systems. Expert Opinion on Drug Delivery 2011, 8:505-519.
23. Huang L.R., Chen F.L., Chen Y.T., Lin Y.M., Kung J.T. Potent induction of long-term CD8+ T cell memory by short-term IL-4 exposure during Tcell receptor stimulation. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3406-3411.
24. Huang Z., Jaafari M.R., Szoka F.C. Disterolphospholipids: non exchangeable lipids and their application to liposomal drug delivery. Angewandte Chemie International Edition In English 2009, 48:4146-4149.
25. Ignatius R., Mahnke K., Rivera M., Hong K., Isdell F., Steinman R.M., Pope M., Stamatatos L. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8+ T-cell responses in vivo. Blood 2000, 96:3505-3513.
26. Iman M., Huang Z., Szoka F.C., Jaafari M.R. Characterization of the colloidal properties, in vitro anti fungal activity, anti leishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B. International Journal of Pharmaceutics 2011, 408:163-172.
27. Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., Barkhordari F., McMaster W.R., Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25:6107-6117.
28. Jaafari M.R., Ghafarian A., Farrokh-Gisour A., Samiei A., Kheiri M.T., Mahboudi F., Barkhordari F., Khamesipour A., McMaster W.R. Immune response and protection assay of recombinant major surface glycoprotein of leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 2006, 24:5708-5717.
29. Kamogawa Y., Minasi L.A., Carding S.R., Bottomly K., Flavell R.A. The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 1993, 75:985-995.
30. Khalil E.A.G., Hassan A.M.E., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., Ibrahim M.E., Kamil A.A., Elsheikh M., Babiker A. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356:1565-1569.
31. Khamesipour A., Rafati S., Davoudi N., Maboudi F., Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian Journal of Medical Research 2006, 123:423-438.
32. Kirby C., Gregoriadis G. Dehydretion-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984, 2:979-984.
33. Lee J.Y., Atochina O., King B., Taylor L., Elloso M., Scott P., Rossman M.D. Beryllium, an adjuvant that promotes gamma interferon production. Infection and Immunity 2000, 68:4032-4039.
34. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic liposomal lipids: from gene carriers to cell signaling. Progress in Lipid Research 2008, 47:340-347.
35. Mahmoodi M., Khamesipour A., Dowlati Y., Rafati S., Momeni A.Z., Emamjomeh M., Hejazi H., Modabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clinical and Experimental Immunology 2003, 134:303-308.
36. Mauel J. Vaccination against Leishmania infections. Current Drug Targets Immune, Endocrine and Metabolic Disorders 2002, 2:201-226.
37. Maurer M., Dondji B., von Stebut E. What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. Medical Microbiology and Immunology 2009, 198:137-146.
38. Modabber F. First generation leishmaniasis vaccines in clinical development: moving, but what next. Current Opinion in Anti-infective Investigational Drugs 2000, 2:35-39.
39. Modabber F., Coler R., Reed S.G. Vaccines against Leishmania. New Generation Vaccines 2009, 273-283. E-Publishing Inc., New York. F. Modabber (Ed.).
40. Morrot A., Hafalla J.C., Cockburn I.A., Carvalho L.H., Zavala F. IL-4 receptor expression on CD8+ T cells is required for the development of protective memory responses against liver stages of malaria parasites. Journal of Experimental Medicine 2005, 202:551-560.
41. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., Fujiwara H., Hamaoka T., Mayumi T. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochemical and Biophysical Research Communications 1997, 240:793-797.
42. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., Nakanishi M., Tanaka K., Mayumi T. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. Journal of Controlled Release 1999, 61:233-240.
43. Noazin S., Modabber F., Khamesipour A., Smith P.G., Moulton L.H., Nasseri K., Sharifi I., Khalil E.A.G., Bernal I.D.V., Antunes C.M.F. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 2008, 26:6759-6767.
44. Noble A., Kemeny D.M. Interleukin-4 enhances interferon-gamma synthesis but inhibits development of interferon-gamma-producing cells. Immunology 1995, 85:357-363.
45. Oussoren C., Storm G. Liposomes to target the lymphatics by subcutaneous administration. Advanced Drug Delivery Reviews 2001, 50:143-156.
46. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26:1709-1724.
47. Platzer C., Richter G., Uberla K., Muller W., Blocker H., Diamantstein T., Blankenstein T. Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. European Journal of Immunology 1992, 22:1179-1184.
48. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annual Review of Immunology 1995, 13:151-177.
49. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to leishmania major in mice. Nature Reviews Immunology 2002, 2:845-858.
50. Scott P., Artis D., Uzonna J., Zaph C. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunological Reviews 2004, 201:318-338.
51. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. Induction of protective immunity with a soluble extract of promastigotes. Journal of Immunology 1987, 139:221-227.
52. ® adjuvant. Vaccine 2002, 20:3292-3303.
53. Stager S., Alexander J., Kirby A.C., Botto M., Rooijen N.V., Smith D.F., Brombacher F., Kaye P.M. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nature Medicine 2003, 9:1287-1292.
54. Taswell C. Limiting dilution assays for the determination of immuno competent cell frequencies. 1. Data analysis. Journal of Immunology 1981, 126:1614-1619.
55. Titus R.G., Marchand M., Boon T., Louis J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunology 1985, 7:545-555.
56. Vangasseri D.P., Cui Z., Chen W., Hokey D.A., Falo L.D., Huang L. Immuno stimulation of dendritic cells by cationic liposomes. Molecular Membrane Biology 2006, 23:385-395.
57. Vanloubbeeck Y., Jones D.E. The immunology of Leishmania infection and the implications for vaccine development. Annals of the New York Academy of Sciences 2004, 1026:267-272.
58. von Stebut E. Cutaneous leishmania infection: progress in pathogenesis research and experimental therapy. Experimental Dermatology 2007, 16:340-346.
59. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Molecular Immunology 2007, 44:3672-3681.
60. Yan W., Chen W., Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. Journal of Controlled Release 2008, 130:22-28.
61. Yan W., Huang L. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. International Journal of Pharmaceutics 2009, 368:56-62.